Sensus Healthcare, Inc. (NASDAQ:SRTS) Given Consensus Rating of “Moderate Buy” by Brokerages

Sensus Healthcare, Inc. (NASDAQ:SRTS) has earned an average recommendation of “Moderate Buy” from the seven ratings firms that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $6.8750.

Several research firms have recently commented on SRTS. Citigroup reiterated a “buy” rating on shares of Sensus Healthcare in a research report on Friday, May 8th. Weiss Ratings restated a “sell (d)” rating on shares of Sensus Healthcare in a research report on Tuesday, April 21st. Finally, Wall Street Zen lowered Sensus Healthcare from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 9th.

Sensus Healthcare Price Performance

NASDAQ:SRTS opened at $3.07 on Friday. Sensus Healthcare has a 52-week low of $2.66 and a 52-week high of $5.92. The stock has a fifty day simple moving average of $3.19 and a 200-day simple moving average of $3.93. The company has a market capitalization of $50.53 million, a PE ratio of -6.53 and a beta of 1.09.

Sensus Healthcare (NASDAQ:SRTS) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.04). Sensus Healthcare had a negative net margin of 34.50% and a negative return on equity of 15.79%. The business had revenue of $3.39 million during the quarter, compared to analyst estimates of $5.32 million.

Institutional Trading of Sensus Healthcare

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Opes Wealth Management LLC acquired a new stake in shares of Sensus Healthcare during the third quarter valued at $50,000. XTX Topco Ltd acquired a new position in Sensus Healthcare in the 4th quarter valued at about $77,000. Jane Street Group LLC purchased a new position in Sensus Healthcare in the 4th quarter valued at about $79,000. Mindset Wealth Management LLC lifted its holdings in Sensus Healthcare by 28.1% in the 3rd quarter. Mindset Wealth Management LLC now owns 50,100 shares of the company’s stock valued at $157,000 after purchasing an additional 11,000 shares in the last quarter. Finally, Ingalls & Snyder LLC purchased a new stake in shares of Sensus Healthcare during the fourth quarter worth about $219,000. 25.30% of the stock is currently owned by hedge funds and other institutional investors.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.